{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:finotonlimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:socazolimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03495427: Phase 2/Phase 3 Interventional Recruiting Prostate Cancer
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:iluzanebart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:lomtegovimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:plozalizumab plevistinag [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:gefurulimab [INN]
Source URL:
Class:
PROTEIN